Supernus to Present at Jefferies Virtual Healthcare Conference
25. Mai 2021 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
24. Mai 2021 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2021 Financial Results
05. Mai 2021 16:01 ET
|
Supernus Pharmaceuticals, Inc.
First quarter 2021 total revenues of $130.9 million, a 38% increase compared to 2020Qelbree™ approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021Qelbree sNDA submission for...
Supernus Announces Paragraph IV ANDA Filing for XADAGO®
04. Mai 2021 20:49 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Host First Quarter 2021 Financial Results Conference Call
27. April 2021 17:44 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
02. April 2021 16:58 ET
|
Supernus Pharmaceuticals, Inc.
Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in the U.S. in 2Q 2021 ROCKVILLE, Md.,...
Supernus to Present at Cowen Healthcare Conference
26. Februar 2021 09:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
25. Februar 2021 16:00 ET
|
Supernus Pharmaceuticals, Inc.
Full year 2020 total revenues of $520.4 million, a 32% increase compared to 2019Full year 2020 operating earnings of $173.7 million, a 17% increase compared to 2019SPN-812 NDA assigned an early April...
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
23. Februar 2021 09:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
22. Februar 2021 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...